Drug Profile
Research programme: neuropsychiatric disorder therapeutics - Intracellular therapies
Alternative Names: IC 200131Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Intra-Cellular Therapies
- Class Behavioural disorder therapies; Mood stabilisers; Small molecules
- Mechanism of Action Dopamine receptor modulators; NR2B N-Methyl D-Aspartate receptor modulators; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mood disorders; Neurological disorders; Psychiatric disorders
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Mood disorders in USA (PO)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Neurological-disorders in USA (PO)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Psychiatric-disorders in USA (PO)